P541: Long-term follow-up results of darvadstrocel for complex perianal fistulas in patients with Crohn@E@s disease: 3-year outcomes from a Japanese phase 3 studyECCO'24Year: 2024
Authors: Uchino, M.(1)*;Ikeuchi, H.(1);Ito, T.(2);Sakakibara, Y.(3);Nakaya, R.(3);Yamaguchi, T.(3);
(1)Hyogo Medical University, Department of Gastroenterological Surgery- Division of Inflammatory Bowel Disease, Nishinomiya, Japan;(2)Sapporo Higashi Tokushukai Hospital, IBD center, Sapporo, Japan;(3)Takeda Pharmaceutical Company Limited, Takeda Development Center, Osaka, Japan;
P542: Clinical decision support tool guided selective intensive induction strategy of ustekinumab in patients with Crohn’s disease: real-world evidenceECCO'24Year: 2024
Authors: Li, Q.(1)*;Tang, J.(1);Shi, L.(2);Lv, X.(3);Chen, W.(4);Guo, Q.(1);Li, M.(1);Gao, X.(1);Chao, K.(1);
(1)The Sixth Affiliated Hospital- Sun Yat-sen University, Department of Gastroenterology, guangzhou, China;(2)The Sixth Affiliated Hospital- Sun Yat-sen University, Center for Clinical Research, Guangzhou, China;(3)The First Affiliated Hospital of Guangxi Medical University, Department of Gastroenterology, Guangxi, China;(4)Peking University Shenzhen Hospital, Department of Gastroenterology, Shenzhen, China;
P543: Patients in trials of moderate-to-severe UC who are exposed to placebo are more likely to suffer harm than those receiving active treatment: The lack of clinical equipoise in traditional study designsECCO'24Year: 2024
Authors: Fine, Z.(1)*;Fear, E.N.(1);St-Pierre, J.(1);Klein, J.A.(1);Choi, N.K.(1);Rubin, D.T.(1,2,3);
(1)University of Chicago, Section of Gastroenterology- Hepatology and Nutrition, Chicago, United States;(2)University of Chicago, Inflammatory Bowel Disease Center, Chicago, United States;(3)University of Chicago, Maclean Center for Clinical Medical Ethics, Chicago, United States;
P544: Ustekinumab safety and effectiveness in ulcerative colitis patients: results from a large real-life study.ECCO'24Year: 2024
Authors: MocciMD FRCP, G.(1)*;Scaldaferri, F.(2);Pugliese, D.(2);Savarino, E.(3);Bodini, G.(4);Cuomo, A.(5);Donnarumma, L.(5);Maconi, G.(6);Cataletti, G.(6);Rodino, S.(7); Sebkova, L.(7);Ferronato, A.(8);Gaiani , F.(9);Marzo , M.(10);Luppino, I.(11);Paese, P.(11);Elisei, W.(12);Monterubbianesi, R.(12);Faggiani, R.(12);Napolitano, D.(2);Grossi, L.(13);Serio, M.(14);Scarcelli, A.(14);Lorenzetti, R.(15);Allegretta , L.(16);Rocco, G.(17);Zampaletta, C.(17);Bolognini, L.(18);Meucci, C.(19);Colucci, R.(20);Tonti, P.(21);Della Valle , N.(22);Piga, R.(23);Forti, G.(24);Onidi, F.M.(1);Usai Satta, P.(1);Picchio, M.(25);Papa, A.(2);Tursi, A.(26);
(1)Arnas- Brotzu Hospital, Department of Internal Medicine- Gastroenterology Unit, Cagliari, Italy;(2)Policlinico Universitario “A. Gemelli” Foundation- IRCCS, Digestive Diseases Centre CEMAD- Department of Medical and Surgical Sciences, Roma, Italy;(3)Azienda Ospedale-Università di Padova AOUP, Gastroenterology Unit, Padua, Italy;(4)IRCCS @D@San Martino@D@ Hospital- University of Genoa, Department of Internal Medicine and Medical Specialties- Division of Gastroenterology-, Genova, Italy;(5)“Umberto I” Hospital- Nocera Inferiore SA, 7 Division of Gastroenterology-, Nocera Inferiore, Italy;(6)“L. Sacco” University Hospital, Gastroenterology Unit- Department Biomedical and Clinical Sciences, Milano, Italy;(7)“Ciaccio-Pugliese” Hospital, Division of Gastroenterology, Catanzaro, Italy;(8)ULSS7 Pedemontana, Digestive Endoscopy Unit-, Santorso, Italy;(9)University of Parma, Gastroenterology and Endoscopy Unit- Department of Medicine and Surgery, Parma, Italy;(10)“Veris-Delli Ponti” Hospital- Scorrano, Division of Gastroenterology-, Scorrano LE, Italy;(11)“Annunziata” Hospital, Division of Gastroenterology, Cosenza, Italy;(12)A.O. “S. Camillo-Folanini”, Division of Gastroenterology, Roma, Italy;(13)“Spirito Santo” Hospital- “G d@E@Annunzio” University, Gastroenterology Unit, Pesca, Italy;(14)“San Salvatore” Hospital, Division of Gastroenterology, Pesaro, Italy;(15)“Nuovo Regina Margherita” Territorial Hospital, Division of Gastroenterology, Roma, Italy;(16)“Santa Caterina Novella” Hospital, Division of Gastroenterology-, Galatina LE, Italy;(17)“Belcolle” Hospital, Division of Gastroenterology, Viterbo, Italy;(18)A.O. “Ospedali Riuniti”- Ancona- Italy, Division of Digestive Diseases- Digestive Endoscopy and Inflammatory Bowel Diseases, Ancona, Italy;(19)“T. Maresca” Hospital, Division of Gastroenterology, Torre del Greco NA, Italy;(20)“San Matteo degli Infermi” Hospital, Digestive Endoscopy Unit, Spoleto PG, Italy;(21)“A. Perrino” Hospital, Division of Gastroenterology, Brindisi, Italy;(22)A.O. “Ospedali Riuniti, Division of Gastroenterology, Foggia, Italy;(23)“S. Pertini” Hospital, Division of Gastroenterology- IBD Unit-, Roma, Italy;(24)“S. Maria Goretti” Hospita, Division of Digestive Endoscopy, Latina, Italy;(25)“P. Colombo” Hospital- ASL Roma 6, Division of General Surgery, Velletri Roma, Italy;(26)Territorial Gastroenterology Service- ASL BAT, Territorial Gastroenterology Service, Andria, Italy;
P545: Long-term efficacy of ozanimod up to 3 years in patient response subgroups identified using group-based trajectory modellingECCO'24Year: 2024
Authors: Schreiber, S.W.(1)*;Feagan, B.G.(2);Sands, B.E.(3);Rieder, F.(4);Torres, J.(3,5,6,7);Liu, Z.(8);Jain, A.(8);Poehler, A.M.(9);Wu, H.(8);Osterman, M.T.(8);Abreu, M.T.(10);Dulai, P.S.(11);
(1)Department of Internal Medicine I- University Hospital Schleswig-Holstein- Kiel University, Internal Medicine I, Kiel, Germany;(2)Robarts Research Institute- Western University, Gastroenterology, London, Canada;(3)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(4)Department of Gastroenterology- Hepatology- and Nutrition- Digestive Disease Institute- Cleveland Clinic, Gastroenterology- Hepatology- and Nutrition, Cleveland, United States;(5)Division of Gastroenterology- Hospital da Luz- Hospital Beatriz Ângelo- and Faculdade de Medicina- Universidade de Lisboa, Gastroenterology, Lisbon, Portugal;(6)Division of Gastroenterology- Hospital Beatriz Ângelo, Gastroenterology, Lisbon, Portugal;(7)Faculdade de Medicina- Universidade de Lisboa, Gastroenterology, Lisbon, Portugal;(8)Bristol Myers Squibb, n/a, Princeton, United States;(9)Bristol Myers Squibb, n/a, Munich, Germany;(10)University of Miami Miller School of Medicine, Gastroenterology, Miami, United States;(11)Feinberg School of Medicine- Northwestern University, Gastroenterology and Hepatology, Chicago, United States;
P547: Improved clinical and radiologic healing of Crohn’s perianal fistulas using a novel coordinated care model optimising medical and surgical treatments: A prospective real-world observational studyECCO'24Year: 2024
Authors: De Gregorio, M.(1,2)*;Winata, L.S.(3);Hartley, I.(1,2);Behrenbruch, C.C.(2,4);Connor, S.J.(5,6);D‘Souza, B.(2,7);Basnayake, C.(1,2);Guerra, G.R.(4,8);Johnston, M.J.(4);Kamm, M.A.(1,2);Keck, J.O.(4);Lust, M.(1);Niewiadomski, O.(1);Ong, E.J.S.(4);Schulberg, J.D.(1,2);Srinivasan, A.(9,10);Sutherland, T.(2,3);Woods, R.J.(4);Wright, E.K.(1,2);Connell, W.R.(1);Thompson, A.J.(1,2);Ding, N.S.(1,2);
(1)St Vincent@E@s Hospital Melbourne, Gastroenterology, Fitzroy, Australia;(2)University of Melbourne, Medicine, Parkville, Australia;(3)St Vincent@E@s Hospital Melbourne, Medical Imaging, Fitzroy, Australia;(4)St Vincent@E@s Hospital Melbourne, Colorectal Surgery, Fitzroy, Australia;(5)Liverpool Hospital Sydney, Gastroenterology, Liverpool, Australia;(6)University of New South Wales South West Sydney Clinical Campuses, Medicine and Health, Sydney, Australia;(7)Northern Hospital, Colorectal Surgery, Epping, Australia;(8)University of Melbourne, Surgery, Parkville, Australia;(9)Austin Health, Gastroenterology, Heidelberg, Australia;(10)Eastern Health, Gastroenterology, Box Hill, Australia;
P548: Ustekinumab shows favourable safety profile and drug persistence rates in patients with Crohn’s Disease – results from a tertiary IBD centreECCO'24Year: 2024
Authors: Snehali, M.(1,2,3,4)*;Ahmed, A.(1);Ghosh, S.(2);Iacucci, M.(2,4,5);Shivaji, U.N.(1,4,5,6);
(1)University Hospitals Birmingham NHS Foundation Trust- Birmingham- UK, Gastroenterology, Birmingham, United Kingdom;(2)APC Microbiome Ireland- College of Medicine and Health- University College Cork- Ireland, Medicine, Cork, Ireland;(3)NH Narayana Health- Bangalore- India, Clinical Research, Bangalore, India;(4)Institute of Immunology and Immunotherapy- University of Birmingham- UK, Immunology and Immunotherapy, Birmingham, United Kingdom;(5)National Institute for Health Research NIHR Birmingham Biomedical Research Centre- University of Birmingham and University Hospitals Birmingham NHS Foundation Trust- UK, Biomedical Research, Birmingham, United Kingdom;(6)Mazumdar-Shaw Medical Centre- A Unit of NH Narayana Health- Bangalore- India, Gastroenterology, Bangalore, India;
P549: Liver stiffness assessed with TE-CAP tends to increase with longer duration of disease in Crohn’s disease: A prospective cohort study for the evaluation of hepatic abnormalities in inflammatory bowel diseaseECCO'24Year: 2024
Authors: Moon, W.(1)*;Seo, K.I.(1);Park, H.J.(1);Lee, J.W.(1);Yun, B.C.(1);Park, S.J.(1);Kim, J.H.(1);Park, M.I.(1);Kim, S.E.(1);Jung, K.(1);
(1)Kosin University College of Medicine, Crohn’s Disease and Ulcerative Colitis Clinic- Division of Gastroenterology and Hepatology- Department of Internal Medicine, Busan, Korea- Republic Of;
P550: Short and long-term outcomes after acute severe ulcerative colitis in adults: A 12 year Canadian experience in the post biologic eraECCO'24Year: 2024
Authors: Vuyyuru, S.(1)*;Alphonsus, L.(2);De Silva, T.A.(2);Archer, M.(3);Solitano, V.(4);Guizzetti, L.(5);Crowley, E.(6);Ponich, T.(7);Beaton, M.(7);Gregor, J.(8);Yan, B.(8);Sey, M.(9);Jairath, V.(10);
(1)Nottingham University Hospitals NHS trust, Gastroenterology, Nottingham, United Kingdom;(2)Western University- Canada, Schulich School of Medicine and Dentistry, London, Canada;(3)Western University- Canada, Lawson Health Research Institute, London, Canada;(4)Humanitas University- Italy, Department of Biomedical Sciences, Milan, Italy;(5)Independent researcher, Independent researcher, London, Canada;(6)Western University- Children’s Hospital- London Health Sciences Centre- Canada, Division of Pediatric Gastroenterology, London, Canada;(7)Schulich School of Medicine- Western University- Canada., Department of Medicine- Division of Gastroenterology, London, Canada;(8)Schulich School of Medicine- Western University- Canada., Department of Medicine- Division of Gastroenterology-, London, Canada;(9)Schulich School of Medicine- Western University- Canada., awson Health Research Institute- Department of Medicine- Division of Gastroenterology-, London, Canada;(10)Schulich School of Medicine- Western University- Canada, Lawson Health Research Institute- Department of Epidemiology and Biostatistics- Department of Medicine- Division of Gastroenterology, London, Canada;
P551: Benefit–risk trade-offs and patient preferences for therapy selection in Ulcerative Colitis: a multi-country preference studyECCO'24Year: 2024
Authors: Gisbert, J.P.(1,2);Schreiber, S.(3);Siegel, C.A.(4,5);Magro, F.(6);Jus, A.(7);Whichello, C.(8);Michaels-Igbokwe, C.(9);Heidenreich, S.(8);Oortwijn, A.(10);Vermeire, S.(11)*;
(1)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-Princesa- Universidad Autónoma de Madrid UAM, Gastroenterology department, Madrid, Spain;(2)Carlos III Health Institute, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Madrid, Spain;(3)Kiel University- University Hospital Schleswig-Holstein, Department of Internal Medicine I, Kiel, Germany;(4)Dartmouth Hitchcock Medical Center, Inflammatory Bowel Disease Center- Section of Gastroenterology & Hepatology, Lebanon- NH, United States;(5)Geisel School of Medicine at Dartmouth, The Dartmouth Institute for Health Policy and Clinical Practice, Hanover- NH, United States;(6)University of Porto, CINTESIS@RISE- Faculty of Medicine, Porto, Portugal;(7)Galapagos B.V., Evidence Generation, Leiden, The Netherlands;(8)Evidera Inc., Patient-Centered Research, London, United Kingdom;(9)Evidera Inc., Patient-Centered Research, Montreal- QC, Canada;(10)Galapagos B.V., Medical Affairs, Leiden, The Netherlands;(11)UZ Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;
P552: Clinical factors associated with ustekinumab therapy persistence in a refractory Crohn’s disease cohortECCO'24Year: 2024
Authors: Corcoran, R.(1)*;Breslin, N.(2);Ryan, B.(2);O@E@Connor, A.(2);O@E@Donnell, S.(2);McKiernan, S.(1);MacCarthy, F.(1);Dunne, C.(1);Hartery, K.(1);McNamara, D.(2);Kevans, D.(1);
(1)St James@E@s Hospital, Department of Gastroenterology, Dublin 8, Ireland;(2)Tallaght University Hospital, Department of Gastroenterology, Dublin 24, Ireland;Trinity Academic Gastroenterology Group (TAAG)
P553: The safety and efficacy of adalimumab 80mg weekly as maintenance therapy in pediatric Crohn’s DiseaseECCO'24Year: 2024
Authors: Cohen-Sela , E.(1);Weintraub , Y.(1);Yerushalmy-Feler , A.(2);Orlanski-Meyer , E.(3);Nassar , R.(4);Magen-Rimon , R.(5);Shamir , R.(1);Shouval , D.S.(1);Matar , M.(1)*;
(1)Schneider Children@E@s Medical Center and the Faculty of Medicine- Tel Aviv University, Institute of Gastroenterology- Nutrition and Liver Diseases, Petach Tikva, Israel;(2)Dana-Dwek Children@E@s Hospital, Pediatric Gastroenterology Institute, Tel Aviv, Israel;(3)Shaare Zedek Medical Center, The Institute of Gastroenterology- Nutrition and Liver Diseases, Jerusalem, Israel;(4)Soroka Medical Center, Pediatric Gastroenterology Unit, Beer Sheva, Israel;(5)Rambam Medical Center, Pediatric Gastroenterology Unit, Haifa, Israel;
P554: Assessment of corticosteroid prescribing trends and appropriateness for management of Inflammatory Bowel Disease in a secondary care centre in New ZealandECCO'24Year: 2024
Authors: Hajelssedig, O.(1,2)*;Clark, E.(1);Edward, P.(1);Kenrick, K.(3);Inns, S.(2);
(1)Nelson Marlborough Health, Medicine, Nelson, New Zealand;(2)University of Otago, Medicine, Wellington, New Zealand;(3)University of Otago, Department of General Practice and Rural Health- Dunedin School of Medicine, Dunedin, New Zealand;
P555: Switching from intravenous vedolizumab to subcutaneous maintains clinical remission even in intensified patients with Inflammatory Bowel Disease. One year follow-up.ECCO'24Year: 2024
Authors: Andres Pascual, L.(1);Arias García , L.(2);Saiz Chumillas , R.M.(2);Chivato Martín-Falquina, I.(2);Sicilia Aladren, B.(2)*;
(1)Hospital Universitario de Burgos, Gastroenterology., Burgos, Spain;(2)Hospital Universitario de Burgos, Gastroenterology, Burgos, Spain;
P556: Immunomodulator and advanced therapies for Induction of clinical remission and response in Crohn’s disease: A systematic review and network meta-analysisECCO'24Year: 2024
Authors: Sinopoulou, V.(1);Gordon, M.(2);Vuyyuru, S.(3)*;Darie, A.M.(3);Radford, S.(4);Shale, M.(3);Moran , G.(5);
(1)University of Central Lancashire, UCLan Cochrane Gut Group, Preston, United Kingdom;(2)University of Central Lancashire, Paediatrics, Preston, United Kingdom;(3)Nottingham University Hospitals- NHS trust, Gastroenterology, Nottingham, United Kingdom;(4)University of Nottingham, Gastroenterology, Nottingham, United Kingdom;(5)Nottingham University Hospitals NHS trust- Nottingham- UK- Nottingham NIHR Biomedical Research Centre- Nottingham- UK- Translational medical sciences- School of Medicine- Faculty of Medicine and Health science- University of Nottingham- UK, Gastroenterology, Nottingham, United Kingdom;
P557: Data communication practices for reporting health care outcomes to improve quality of care: A scoping reviewECCO'24Year: 2024
Authors: Ali, M.(1)*;Visser, E.(2);West, R.(2);Noord, D.V.(2);Woude, C.J.V.D.(3);Deen, W.V.(1);
(1)Erasmus School of Health Policy & Management- Erasmus University Rotterdam, Health Technology Assessment, Rotterdam, The Netherlands;(2)Franciscus Gasthuis & Vlietland, Department of Gastroenterology & Hepatology, Rotterdam, The Netherlands;(3)Erasmus MC-University Medical Centre, Department of Gastroenterology & Hepatology, Rotterdam, The Netherlands;
P558: Clinical Effectiveness and Safety of Vedolizumab vs. Infliximab in Biologic-Naïve Ulcerative Colitis Patients: A Brazilian Real-World Multicentric Observational StudyECCO'24Year: 2024
Authors: Ferreira, S.(1)*;Chebli, J.M.F.(2);Parra, R.(3);Yukie Sassaki, L.(4);de Mello, M.K.(5);Luporini, R.L.(6);Chebli, L.A.(7);Firmino Nóbrega, F.J.(8);da Silva, B.C.(9);Dutra, R.D.M.(4);de Oliveira Vasconcelos, J.R.(1);Moraes Sales, M.P.(2);Féres, O.(10);Parente, J.M.L.(11);Troncon, L.E.D.A.(12);
(1)Hospital das Clínicas- Ribeirão Preto Medical School, Medicine, Ribeirão Preto, Brazil;(2)Division of Gastroenterology- Federal University of Juiz de Fora, Medicine, Juiz de Fora, Brazil;(3)Hospital das Clínicas- Ribeirão Preto Medical School, Surgery and Anatomy, Ribeirão Preto, Brazil;(4)São Paulo State University Unesp- Medical School, Internal Medicine, Botucatu, Brazil;(5)University of Vale do Itajaí, Medicine, Itajaí, Brazil;(6)Federal University of São Carlos UFSCar, Medicine, São Carlos, Brazil;(7)Division of Gastroenterology- Federal University of Juiz de Fora, Medicine, Juiz de Forra, Brazil;(8)Lauro Wanderley Hospital- Federal University of Paraíba, Gastroenterology, João Pessoa, Brazil;(9)Hospital da Bahia, Gastroenterology, Salvador, Brazil;(10)Ribeirão Preto Medical School- University of São Paulo, Surgery and Anatomy, Ribeirão Preto, Brazil;(11)Faculty of Medicine of the Federal University of Piauí, Gastroenterology, Teresina, Brazil;(12)Ribeirão Preto Medical School- University of São Paulo, Medicine, Ribeirão Preto, Brazil;
P559: Descriptive observational pilot study about the use of Virtual Reality (VR) in patients with Inflammatory Bowel Disease (IBD) and biological treatmentECCO'24Year: 2024
Authors: Díaz Molina, R.J.(1)*;Comesaña Castellar, C.(1);Crespi Rigo, J.(2);Radu Tomsa, C.(2);Quesada Bauzá, P.(2);Porcel Corral, I.(2);Ginard Vicens, D.(1);
(1)Hospital Universitario Son Espases, Gastroenterology, Palma De Mallorca, Spain;(2)University of the Balearic Islands, Faculty of Pedagogy, Palma de Mallorca, Spain;
P560: The impact of reactive point-of-care drug level measurement on the medium-term course of inflammatory bowel diseaseECCO'24Year: 2024
Authors: Ivány, E.(1)*;Farkas, B.(1);Resál, T.(1);Bacsur, P.(1);Bálint, A.(1);Farkas, K.(1);Molnár, T.(1);
(1)Szent-Györgyi Albert Medical Centre- University of Szeged, Department of Internal Medicine, Szeged, Hungary;
